Research ArticleNuclear Oncology
Optimized Conditions for Chelation of Yttrium-90-DOTA Immunoconjugates
David L. Kukis, Sally J. DeNardo, Gerald L. DeNardo, Robert T. O'Donnell and Claude F. Meares
Journal of Nuclear Medicine December 1998, 39 (12) 2105-2110;
David L. Kukis
Sally J. DeNardo
Gerald L. DeNardo
Robert T. O'Donnell


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Optimized Conditions for Chelation of Yttrium-90-DOTA Immunoconjugates
David L. Kukis, Sally J. DeNardo, Gerald L. DeNardo, Robert T. O'Donnell, Claude F. Meares
Journal of Nuclear Medicine Dec 1998, 39 (12) 2105-2110;
Jump to section
Related Articles
- No related articles found.
Cited By...
- 89Zr-Chloride Can Be Used for Immuno-PET Radiochemistry Without Loss of Antigen Reactivity In Vivo
- Direct Antilymphoma Effects on Human Lymphoma Cells of Monotherapy and Combination Therapy with CD20 and HLA-DR Antibodies and 90Y-Labeled HLA-DR Antibodies
- Does Paclitaxel (Taxol) Given after 111In-Labeled Monoclonal Antibodies Increase Tumor-Cumulated Activity in Epithelial Cancers?
- Evaluation of an 111In-DOTA-Rhenium Cyclized {alpha}-MSH Analog: A Novel Cyclic-Peptide Analog with Improved Tumor-Targeting Properties
- Metabolite Production in Patients with Lymphoma After Radiometal-Labeled Antibody Administration
- Radioimmunotherapy with 111In/90Y-2IT-BAD-m170 for Metastatic Prostate Cancer